Merck Committed To Animal Health, Consumer Care, Frazier Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In a week that saw Pfizer sell a non-core business to Nestle for five times sales, CEO Ken Frazier says Merck’s non-core businesses “complement” its R&D-driven pharma business.
You may also be interested in...
Alogliptin Rejection Dents Takeda’s Diabetes Franchise
Latest “complete response” letter for Takeda’s DPP-4 inhibitor is “not specific” to cardiovascular outcomes. But the delay does not bode well for entry into the crowded DPP-4 space.
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?